Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that, following multiple interactions with and recent feedback from the U.S. Food and Drug Administration (FDA), it has resubmitted its New Drug Application (NDA) for sotagliflozin as an adjunct to insulin therapy for glycemic control in people with type 1 diabetes and chronic kidney disease (CKD). Safe Harbor Statement Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therap ...